O
PRNB

OrbiMed’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

OrbiMed’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,605,713
Closed -$45.3M – 151
2019
Q3 		$45.3M Hold
1,605,713
– – 0.86% 35
2019
Q2 		$53.3M Sell
1,605,713
-1,000,000
-38% -$31.2M 0.83% 37
2019
Q1 		$88.6M Hold
2,605,713
– – 1.37% 20
2018
Q4 		$71.4M Hold
2,605,713
– – 1.32% 22
2018
Q3 		$76.1M Buy
+2,605,713
New +$73.5M 0.92% 30

Other funds holding PRNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed's PRNB Position: Q4 2019 in Review

OrbiMed sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q4 2019, closing a stake of 1,605,713 shares — an estimated $45.3M sold.

OrbiMed first reported a position in PRNB in Q3 2018 and held it in 5 quarters. The position peaked at $88.6M in Q1 2019. 115 funds tracked by Wall St. Rank hold PRNB as of Q4 2019.

  • OrbiMed reported no remaining Principia Biopharma Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • OrbiMed sold 1,605,713 Principia Biopharma Inc. Common Stock shares in Q4 2019, an estimated $45.3M.
  • OrbiMed first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 5 quarters.
  • OrbiMed's Principia Biopharma Inc. Common Stock position peaked at $88.6M in Q1 2019.
  • 115 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q4 2019.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.